Efficacy, Safety and Pharmacokinetics of DTG with RIF

This trial is studying whether dolutegravir (DTG), an HIV medication, works effectively and safely when taken alongside rifampicin (RIF), an antibiotic commonly used to treat tuberculosis (TB), in people who have both HIV and TB. **You may be eligible if...** - You are HIV-positive and have never been on HIV treatment (or had less than 2 weeks of it) - You are 18 years or older - You have been diagnosed with TB and are taking rifampicin-based TB treatment - Your liver and kidney function are within acceptable ranges - Your weight is above 40 kg (about 88 lbs) - You do not have other serious active infections (besides oral thrush or disseminated MAC) **You may NOT be eligible if...** - You have been on HIV treatment for more than 2 weeks - You have significant liver problems (ALT more than 5 times the normal limit) - Your kidneys are not working well (eGFR below 60) - You are severely anemic (hemoglobin below 7 mg/L) - You have another serious active opportunistic infection Talk to your doctor to see if this trial is right for you.